*Mycobacterium tuberculosis* killed more people than any other pathogen in 2016, when over 10 million active cases were estimated, and 1.7 million patients died.[@B1] In 2014, the World Health Organization (WHO) set a target to 'END TB' by 2035, acknowledging that success depends on the development of better preventative, diagnostic and therapeutic interventions. The global emergence of antimicrobial resistance poses a major challenge. Despite a call for universal access to drug susceptibility testing to direct individualised therapies, high costs and skills shortages mean it is unavailable in many countries with greatest need. Consequently, only 22% of an estimated 600,000 patients requiring treatment for multidrug-resistant tuberculosis were diagnosed and treated in 2016,[@B1] facilitating the onward transmission of multidrug-resistant strains.[@B2]

The Xpert MTB/RIF (Cepheid, Sunnyvale, California, USA) assay has partially eased the global diagnostic need. It uses polymerase chain reaction technology to identify both *M. tuberculosis* complex and mutations in the *rpoB* gene (predictive of multidrug resistance) directly from clinical samples.[@B3] However, as it targets only a few potential resistance-conferring mutations, antimicrobial susceptibility cannot be reliably inferred from a negative result.[@B4] To direct individualised therapies, a diagnostic assay is needed to determine which drugs to give, in addition to which to avoid.

Advances in whole-genome sequencing mean it is now the most promising solution to the need for universal drug susceptibility testing. It is faster, more scalable, and likely to become cheaper than phenotypic testing.[@B5] As the number of genomic sites whole-genome sequencing covers are virtually unrestricted, it should be possible to infer *M. tuberculosis* antimicrobial susceptibility from the absence of resistance-conferring mutations.[@B6] Here we assess how well this performs for first-line anti- tuberculosis drugs, considering WHO target product profiles for new molecular assays,[@B7] and whether whole-genome sequencing can be used to accurately direct anti-tuberculosis therapy.

Methods
=======

Sample selection
----------------

Collections of *M. tuberculosis* complex isolates unenriched for resistance and largely sequenced prospectively for routine diagnostic reasons, or for disease surveillance, were included from Germany, Italy, the Netherlands and the UK. Collections enriched for antimicrobial resistance, were included from across six continents ([Table1](#T1){ref-type="table"}, [Supplement S1](#SD1){ref-type="supplementary-material"}). Analyses of both the unenriched and complete collection were planned.

###### Number of isolates by country and drug resistance profile

  Country of sample origin   Time period of isolation   Enriched for resistance                   Susceptible to all 4 drugs   Susceptible to 3 drugs, with missing pyrazinamide result   Isoniazid resistant, rifampicin susceptible   Isoniazid susceptible, rifampicin resistant   Isoniazid resistant, rifampicin resistant   Other pattern   Total
  -------------------------- -------------------------- ----------------------------------------- ---------------------------- ---------------------------------------------------------- --------------------------------------------- --------------------------------------------- ------------------------------------------- --------------- -------
  Australia                  2006-2016                  Yes                                       0                            0                                                          4                                             0                                             38                                          0               42
  Belgium                    2007-2015                  Yes                                       121                          0                                                          2                                             0                                             97                                          14              234
  Canada                     2003-2014                  Yes                                       11                           1,118                                                      164                                           14                                            24                                          12              1343
  China                      2009-2012                  Yes                                       0                            44                                                         0                                             0                                             236                                         0               280
  Germany                    1998-2015                  No                                        248                          0                                                          9                                             1                                             13                                          2               273
  Italy                      2008-2016                  Yes and No[\*](#TFN1){ref-type="tblfn"}   82                           1                                                          9                                             0                                             132                                         2               226
  Netherlands                1993-2016                  No                                        420                          42                                                         24                                            1                                             149                                         31              667
  Pakistan                   2014-2015                  Yes                                       47                           5                                                          11                                            6                                             345                                         1               415
  Peru                       1997-2009                  Yes                                       24                           12                                                         49                                            18                                            199                                         13              315
  Russia                     2008-2010                  Yes                                       282                          0                                                          116                                           15                                            407                                         22              842
  Serbia                     2008-2014                  Yes                                       0                            0                                                          0                                             0                                             105                                         0               105
  South Africa               2012-2014                  Yes                                       593                          11                                                         37                                            69                                            151                                         130             991
  Spain                      2013-2015                  Yes                                       45                           3                                                          5                                             2                                             8                                           1               64
  Swaziland                  2009-2010                  Yes                                       2                            130                                                        14                                            4                                             116                                         7               273
  Thailand                   1998-2013                  Yes                                       0                            53                                                         7                                             4                                             188                                         0               252
  UK                         2009-2017                  Yes and No[\*](#TFN1){ref-type="tblfn"}   3,036                        82                                                         167                                           6                                             442                                         154             3,887
  Total                                                                                           4911                         1501                                                       618                                           140                                           2650                                        389             10209

More than one collection was derived from Italy and the UK, some enriched and some not enriched for resistance. See supplement for details.

Sequencing
----------

Isolates were sequenced on Illumina platforms and reads processed by the Public Health England bioinformatics pipeline at Genomics England,[@B8] as described.[@B6] Reads were mapped to the pan- susceptible *M. tuberculosis* reference genome (Genbank NC_000962.2) using Stampy (v.1.0.17)[@B9], with repetitive regions masked. SAMtools mpileup[@B10] (v.0.1.18) made variant-calls based on a minimum depth of 5X and at least one read on each strand. Mixed-calls were assigned where minority alleles composed \>10% of read depth. Insertions and deletions were determined using Cortex (v.1.0.5.21).[@B11]

Drug susceptibility testing and prediction
------------------------------------------

Phenotypic drug susceptibility testing was performed locally using MGIT 960 (Becton Dickinson, New Jersey, USA), 7H10 or Löwenstein-Jensen agar, or by microscopic-observation drug- susceptibility (MODS), with method-specific critical concentrations for isoniazid (MGIT 0.1-0.2μg/mL; Agar 0.2μg/mL; MODS 0.4μg/mL), rifampicin (MGIT 1.0μg/mL; 40μg/mL Agar), ethambutol (MGIT 5.0μg/mL; Agar 0.2μg/mL), and pyrazinamide (100μg/mL). Not all laboratories routinely tested all agents (S1). Genotypic predictions were based on mutations in, or upstream of, genes associated with resistance to isoniazid (*ahpC, inhA, fabG1, katG*), rifampicin (*rpoB*), ethambutol (*embA, embB, embC*), and pyrazinamide (*pncA*).[@B6] A knowledgebase of mutations predicting antimicrobial resistance, or not, was informed by (i) the molecular targets of WHO-recommended line-probe assays (MTBDR*plus*, MTBDR*sl* v1.0, HAIN Lifesciences, Germany), (ii) a systematic literature review,[@B12] (iii) the CDC, Atlanta, USA, panel and (iv) two recent studies, with no isolates in common with this study ([S2](#SD1){ref-type="supplementary-material"}),[@B6] of which one became available after this study commenced.[@B13]

Isolates containing resistance-mutations were predicted phenotypically resistant, whereas isolates containing only wild-type sequence, phylogenetic mutations,[@B6] or mutations considered consistent with susceptibility, were predicted susceptible. Predictions were withheld for isolates containing mutations affecting target genes but of unknown association, or where no nucleotide-call could be determined at a resistance-associated site. In these circumstances, the genotype was reported 'unknown' or 'failed', respectively. Using phenotypic results as a gold-standard, sensitivity, specificity, negative and positive predictive value were calculated for the correct assignment of susceptibility or resistance. Primary analyses excluded phenotypes without a prediction.

Laboratory error was assumed where three or more phenotypes were discordant with an isolate's genotype, or where susceptible phenotypes were recorded despite the presence of high-level resistance *katG* S315T mutations for isoniazid, or *rpoB* S450L mutations for rifampicin.[@B14] Such isolates were excluded from further analysis.

Analysis was performed using STATA (Texas, USA, v13.1). No institutional review board approval was required except in Thailand, it was granted through Mahidol University (Si029/2557).

The study was first designed by TMW,TEAP,DWC, with subsequent contributions from others (supplement). Data were gathered at participating centres. Initial analysis was performed by TMW,TEAP,ASW,ZI,MH,SL,DW,PF,PM with later input from others (supplement). TMW wrote the first draft. TMW vouches for the analysis and had full access to the data; all authors agreed to publication.

Results
=======

10,290 isolates were available for the study. 81 (0.8%) were excluded due to likely laboratory error. 10,209 isolates remained, for which full first-line phenotypic profiles were available for 7,516 (73.6%), and partial profiles for the remainder. 4,911 (48.1%) isolates were phenotypically susceptible to all drugs ([Table 1](#T1){ref-type="table"}).

For each isolate, the complete sequence of nine genes and their promoter regions was interrogated to make genotypic predictions of each available phenotypic result. Predictions could be made for 8,405/8,976 (93.6%) resistant and 26,879/28,746 (93.5%) susceptible phenotypes. The remainder contained uncharacterised mutations, or missing key nucleotide calls. For isoniazid and rifampicin, ethambutol and pyrazinamide, sensitivity (proportion of resistant phenotypes predicted resistant) was 97.1%, 97.5%, 94.6% and 91.3%, and specificity (proportion of susceptible phenotypes predicted susceptible) was 99.0%, 98.8%, 93.6% and 96.8%, respectively. By comparison, an in-silico prediction of the results that would have been obtained from WHO-recommended molecular assays (Xpert MTB/RIF, MTBDR*plus*, MTBDR*sl* v1.0) had a significantly lower sensitivity than whole-genome sequencing for isoniazid, rifampicin and ethambutol (p\<0.001), but greater specificity for isoniazid and ethambutol (p\<0.001) ([Table 2a,b](#T2){ref-type="table"}).

###### Prediction of individual drug phenotypes

                                                                                                                                                      Resistant phenotype, n (%)   Susceptible phenotype, n (%)                                                                                                                                                                                                                      
  --------------------------------------------------------------------------------------------------------------------------------------------------- ---------------------------- ------------------------------ ----- ------ ------ ------ ------ ------ ----------------------- ------------------- -------------------- ------------------- ------------------- --------------------- --------------------- ------ ------ ------ -----
  \(a\) All isolates                                                                                                                                                                                                                                                                                                                                                                                                                 
  Isoniazid                                                                                                                                           3067                         90                             93    44     3294   65     6313   215    117                     6710                97.1 (96.5-97.7)     99.0 (98.7-99.2)    97.9 (97.4-98.4)    98.6 (98.3-98.9)      93.1                  94.1   4.7    32.9   
  Rifampicin                                                                                                                                          2743                         69                             7     84     2903   85     6763   232    147                     7227                97.5 (96.9-98.1)     98.8 (98.5-99.0)    97.0 (96.3-97.6)    99.0 (98.7-99.2)      94.5                  93.6   4.6    28.7   
  Ethambutol                                                                                                                                          1410                         81                             94    55     1640   468    6835   781    70                      8154                94.6 (93.3-95.7)     93.6 (93.0-94.1)    75.1 (73.0-77.0)    98.8 (98.5-99.1)      86.0                  83.8   10.2   16.7   
  Pyrazinamide                                                                                                                                        863                          82                             117   77     1139   204    6146   197    108                     6655                91.3 (89.3-93.0)     96.8 (96.3-97.2)    80.9 (78.4-83.2)    98.7 (98.4-99.0)      75.8 92.4             6.4    14.6          
  \(b\) In silico prediction of performance of MTB/RIF Xpert and HAIN MTBDRplus/MTBDRsl line-probe assays for all isolates                                                                                                                                                                                                                                                                                                           
  Isoniazid                                                                                                                                           2886                         355                            53    3294   27     6675   8      6710   89.0 (87.9-90.1)†       99.6 (99.4-99.7)†   99.1 (98.7-99.4)†    95.0 (94.4-95.5)†   0.6 32.9                                                                             
  Rifampicin                                                                                                                                          2669                         143                            91    2903   129    6826   272    7227   94.9 (94.0-95.7)†98.1   (97.8-98.4)‡        95.4 (94.5-96.1)‡    97.9 (97.6-98.3)†   3.6                 28.7                                                             
  Ethambutol                                                                                                                                          961                          641                            38    1640   241    7895   18     8154   60.0 (57.5-62.4)†       97.0 (96.6-97.4)†   80.0 (77.6-82.2)‡    92.5 (91.9-93.0)†   0.6                 16.7                                                             
  Pyrazinamide                                                                                                                                                                                                                                                                                                                                                                                                                       
  \(c\) Collections from Germany, Italy, the Netherlands and the UK, unenriched for resistance                                                                                                                                                                                                                                                                                                                                       
  Isoniazid                                                                                                                                           314                          8                              9     4      335    15     3770   104    90                      3979                97.5 (95.2-98.9)     99.6 (99.3-99.8)†   95.4 (92.6-97.4)‡   99.8 (99.6-99.9)†     93.7                  94.7   4.8    7.8    
  Rifampicin                                                                                                                                          126                          0                              0     9      135    31     3958   103    116                     4208                100.0 (97.1-100.0)   99.2                (98.9-99.5)§        80.3 (73.2-86.2)†     100.0 (99.9-100.0)†   93.3   94.1   5.2    3.1
  Ethambutol                                                                                                                                          72                           1                              0     0      73     47     3711   458    36                      4252                98.6 (92.6-100.0)    98.7 (98.3-99.1)†   60.5 (51.1-69.3)†   100.0 (99.8-100.0)†   98.6                  87.3   11.4   1.7    
  Pyrazinamide                                                                                                                                        109                          6                              4     6      125    30     4003   14     58                      4105                94.8 (89.0-98.1)     99.3 (98.9-99.5)†   78.4 (70.6-84.9)    99.9 (99.7-99.9)†     87.2                  97.5   1.9    3.0    
  \(d\) In silico prediction of performance of MTB/RIF Xpert and HAIN MTBDRplus/MTBDRsl line-probe assays for collections unenriched for resistance                                                                                                                                                                                                                                                                                  
  Isoniazid                                                                                                                                           295                          36                             4     335    10     3965   4      3979   89.1 (85.3-92.3)†       99.7 (99.5-99.9)    96.7 (94.1-98.4)     99.1 (98.8-99.4)†   0.2                                                                                  
  Rifampicin                                                                                                                                          114                          11                             10    135    22     3957   229    4208   91.2 (84.8-95.6)†       99.4 (99.2-99.7)    83.8 (76.5-89.6)     99.7 (99.5-99.9)†   5.5                                                                                  
  Ethambutol                                                                                                                                          57                           16                             0     73     29     4220   3      4252   78.1 (66.9-86.9)†       99.3 (99.0-99.5)§   66.3 (55.3-76.1)     99.6 (99.4-99.8)†   0.1                                                                                  
  Pyrazinamide                                                                                                                                                                                                                                                                                                                                                                                                                       

PPV = Positive Predictive Value; NPV = Negative Predictive Value; R=resistant; S=susceptible; U=mutation of unknown association present; F=genotypic prediction failed due to missing data around a genomic resistance locus; All % results based on R/S genotypic predictions only, excluding U and F except where \* for which denominator includes R, S, U and F. †p≤0.001 , ‡p≤0.01, and §p≤0.05 comparing sensitivity, specificity, NPV and PPV for each drug for (b) and (c) against (a), and comparing (d) against (c); p\>0.05 for all results not marked †, ‡ or §. In silico predictions of resistance for Xpert and HAIN assays were based on the presence of non-wild type sequence within the genomic regions interrogated by these assays. \'F\' was reported in the presence of minority alleles at relevant sites, just as for WGS predictions.

The negative predictive value (proportion of concordant susceptible predictions) was over 98.5% for all four drugs. Although dependent on prevalence, this also varied with isolates' background phenotypic profiles. For example, at 20% prevalence of pyrazinamide resistance, the expected negative predictive value for pyrazinamide was 93.6% and 99.0% for isolates susceptible and resistant to the other three drugs, respectively ([Table 3](#T3){ref-type="table"}, [S3](#SD1){ref-type="supplementary-material"}).

                 Phenotypic profiles   R     S    U    F     Total   R     S       U     F     Total   Prevalence of resistance among each of the listed drug profiles, %   Sensitivity, %   Specificity, %   PPV, %   NPV,%       Expected NPV at given prevalence of resistance based on simulations, % (95% CI)\*   Calculated NPV at 20% prevalence of resistance, % (see [table S3](#SD1){ref-type="supplementary-material"})   Calculated NPV at 40% prevalence of resistance, % (see [table S3](#SD1){ref-type="supplementary-material"})
  -------------- --------------------- ----- ---- ---- ----- ------- ----- ------- ----- ----- ------- -------------------------------------------------------------------- ---------------- ---------------- -------- ----------- ----------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------- -------------------------------------------------------------------------------------------------------------
  Isoniazid      -SSS                  391   30   18   12    451     21    4,653   133   104   4,911   8.4                                                                  93               100              95       99.4        99.3-100                                                                            98.2                                                                                                          95.4
  -RSS           459                   21    20   6    506   7       85    5       1     98    83.8    96                                                                   92               98               80.2     83.5-100    98.8                                                                                96.9                                                                                                          
  -RRS           424                   3     13   4    444   2       2     2       0     6     98.7    99                                                                   50               100              40.0     73.7-85.6   99.6                                                                                99.1                                                                                                          
  -SRS           24                    4     1    0    29    0       10    1       0     11    72.5    86                                                                   100              100              71.4     90.5-95.6   96.6                                                                                91.3                                                                                                          
  -SSR           24                    1     2    1    28    0       95    6       3     104   21.2    96                                                                   100              100              99.0     98.5-99.7   99                                                                                  97.4                                                                                                          
  -RRR           662                   3     11   4    680   0       0     0       0     0     100.0   100                                                                  .                100              0.0      73.7-85.6   n/a                                                                                 n/a                                                                                                           
  -RSR           217                   3     5    5    230   0       3     0       0     3     98.7    99                                                                   100              100              50.0     73.7-85.6   99.7                                                                                99.1                                                                                                          
  -SRR           13                    0     0    2    15    0       0     0       0     0     100.0   100                                                                  .                100              .        73.7-85.6   n/a                                                                                 n/a                                                                                                           
                                                                                                                                                                                                                                                                                                                                                                                                                                     
  Rifampicin     S-SS                  74    16   0    8     98      30    4,632   126   123   4,911   2.0                                                                  82               99               71       99.7        99.3-100                                                                            95.7                                                                                                          89.3
  S-RS           6                     0     0    0    6     1       9     1       0     11    35.3    100                                                                  90               86               100.0    97.8-99.5   100                                                                                 100                                                                                                           
  S-SR           1                     2     0    0    3     0       100   3       1     104   2.8     33                                                                   100              100              98.0     99.3-100    85.7                                                                                69.2                                                                                                          
  S-RR           0                     0     0    0    0     0       0     0       0     0     .       .                                                                    .                .                .        .           n/a                                                                                 n/a                                                                                                           
  R-SS           464                   20    1    21   506   18      424   3       6     451   52.9    96                                                                   96               96               95.5     95.8-98.6   98.9                                                                                97.2                                                                                                          
  R-RS           424                   7     2    11   444   4       25    0       0     29    93.9    98                                                                   86               99               78.1     76.2-86.6   99.5                                                                                98.8                                                                                                          
  R-SR           218                   4     0    8    230   7       20    0       1     28    89.1    98                                                                   74               97               83.3     77.9-87.9   99.4                                                                                98.4                                                                                                          
  R-RR           665                   2     0    13   680   10      3     0       2     15    97.8    100                                                                  23               99               60.0     76.2-86.6   99.7                                                                                99.1                                                                                                          
                                                                                                                                                                                                                                                                                                                                                                                                                                     
  Ethambutol     SS-S                  1     9    1    0     11      4     4,399   472   36    4,911   0.2                                                                  10               100              20       99.8        98.8-99.9                                                                           81.6                                                                                                          62.5
  RS-S           21                    5     3    0    29    31      376   40      4     451   6.0     81                                                                   92               40               98.7     98.8-99.9   95.1                                                                                87.8                                                                                                          
  SR-S           4                     2     0    0    6     1       93    3       1     98    5.8     67                                                                   99               80               97.9     98.8-99.9   92.2                                                                                81.7                                                                                                          
  RR-S           375                   20    30   19   444   203     241   48      14    506   46.7    95                                                                   54               65               92.3     93.4-96.7   97.7                                                                                94.1                                                                                                          
  SS-R           0                     0     0    0    0     1       81    22      0     104   0.0     .                                                                    99               0                100.0    98.8-99.9   n/a                                                                                 n/a                                                                                                           
  RS-R           12                    2     1    0    15    7       20    1       0     28    34.9    86                                                                   74               63               90.9     95.7-98.1   95.4                                                                                88.6                                                                                                          
  SR-R           0                     0     0    0    0     0       3     0       0     3     0.0     .                                                                    100              .                100.0    98.8-99.9   n/a                                                                                 n/a                                                                                                           
  RR-R           625                   9     26   20   680   150     50    25      5     230   74.7    99                                                                   25               81               84.7     82.0-88.2   98.6                                                                                96.4                                                                                                          
                                                                                                                                                                                                                                                                                                                                                                                                                                     
  Pyrazinamide   SSS-                  74    28   0    2     104     12    4,826   13    60    4,911   2.1                                                                  73               100              86       99.4        98.6-99.6                                                                           93.6                                                                                                          84.5
  RSS-           13                    8     4    3    28    5       431   2       13    451   5.8     62                                                                   99               72               98.2     98.6-99.6   91.2                                                                                79.6                                                                                                          
  RRS-           166                   25    22   17   230   49      374   68      15    506   31.3    87                                                                   88               77               93.7     95.5-97.7   96.4                                                                                91                                                                                                            
  SRS-           0                     3     0    0    3     0       97    0       1     98    3.0     0                                                                    100              .                97.0     98.6-99.6   80                                                                                  60                                                                                                            
  RRR-           532                   15    83   50   680   107     216   105     16    444   60.5    97                                                                   67               83               93.5     87.3-91.0   99                                                                                  97.3                                                                                                          
  SRR-           0                     0     0    0    0     0       6     0       0     6     0.0     .                                                                    100              .                100.0    98.6-99.6   n/a                                                                                 n/a                                                                                                           
  RSR-           10                    2     1    2    15    0       28    0       1     29    34.1    83                                                                   100              100              93.3     95.0-97.3   96                                                                                  90                                                                                                            
  SSR-           0                     0     0    0    0     0       11    0       0     11    0.0     .                                                                    100              .                100.0    98.6-99.6   n/a                                                                                 n/a                                                                                                           
                                                                                                                                                                                                                                                                                                                                                                                                                                     

Phenotypic profiles are listed in the following order: Isoniazid, Rifampicin, Ethambutol, Pyrazinamide. \'-\' under \'Phenotypic profiles\' marks the drug phenotype being assessed. PPV = Positive Predictive Value; NPV = Negative Predictive Value; R=resistant; S=susceptible; U=mutation of unknown association present; F=genotypic prediction failed due to missing data around a genomic resistance locus; All % results based on R/S genotypic predictions only, excluding U and F. Expected NPV was calculated as follows: specificity x (1-prevlence) / (specificity x (1-prevlence)+(1-sensitivity) x prevalence). \* indicates that for prevalence \<10% or \>90%, simulated values are given for 10% and 90% respectively as simulations were not performed below or above these values.

As some collections included clustered isolates, the analysis was repeated after randomly selecting one representative among genomically indistinguishable isolates, and again from isolates within five single nucleotide polymorphisms of another. No significant change in sensitivity or specificity was observed for any drugs (p\>0.1, [S4](#SD1){ref-type="supplementary-material"}).

To reflect the emerging practice of routinely sequencing isolates for clinical care, the analysis was repeated for the subset of 4,397 isolates from German, Italian, Dutch and UK collections that were not enriched for resistance. Among these isolates, 335 (7.6%) were isoniazid resistant and 125 (2.8%) multidrug-resistant. For each drug, specificity and negative predictive values increased, whilst positive predictive values (the proportion of concordant resistant predictions) decreased relative to the overall results. There was no significant change in sensitivity ([Table 2c](#T2){ref-type="table"}).

Predicting complete phenotypic profiles
---------------------------------------

For DNA sequencing to help individualise therapy, a minimum requirement is that all first-line antimicrobial phenotypes are predicted. Phenotypic profiles were thus predicted for 7,516 isolates with phenotypic data available for all first-line drugs ([S1&6](#SD1){ref-type="supplementary-material"}). 'Unknown' or 'failed' was reported for at least one drug for 1,651 (22.0%) profiles. 5,865 (78.0%) were predicted completely, of which 5,250 (89.5%) were predicted correctly ([S5](#SD1){ref-type="supplementary-material"}). Among the 5,865 profiles, 4,007 were phenotypically pan-susceptible, of which 3952 (98.6%) were predicted correctly ([Table 4](#T4){ref-type="table"}).

###### Genotypic drug profile predictions of pan-susceptibility

  Prediction                                                                                                               Genotypic drug profile      Number predicted to have drug profile   Number predicted to have drug profile that are phenotypic ally pansusceptible (%)   Sensitivity %   Specificity %   PPV %         NPV %   Predictions made %         
  ------------------------------------------------------------------------------------------------------------------------ --------------------------- --------------------------------------- ----------------------------------------------------------------------------------- --------------- --------------- ------------- ------- -------------------- -- -- --
  \(a\) Predicted pan-susceptible                                                                                          S                           S                                       S                                                                                   S               4,037           3952 (97.9)                                      
                                                                                                                                                                                                                                                                                                                                                                    
  \(b\) Predicted pansusceptible after inferring that \'U\' mutations are consistent with susceptibility in this context   S                           S                                       S                                                                                   U               11              11 (100)                                         
  S                                                                                                                        S                           U                                       S                                                                                   410             399 (97.3)                                                       
  S                                                                                                                        S                           U                                       U                                                                                   2               2 (100)                                                          
  S                                                                                                                        U                           S                                       S                                                                                   93              88 (94.6)                                                        
  S                                                                                                                        U                           U                                       S                                                                                   29              29 (100)                                                         
                                                                                                                           Total                       4,582                                   4481 (97.8)                                                                                                                                                          
  \(c\) Predicted to have some phenotypic resistance                                                                       R                           S                                       R or S                                                                              397             18 (4.5)                                                         
  S                                                                                                                        At least one R, no U or F   158                                     36 (22.8)                                                                                                                                                            
  R                                                                                                                        R                           R or S                                  1273                                                                                1 (0.1)                                                                          
                                                                                                                           Total                       1828                                    55 (3.0)                                                                                                                                                             
                                                                                                                           95.4                        98.6                                    97.0                                                                                97.9            78.0                                                             
  94.6                                                                                                                     98.8                        97.0                                    97.8                                                                                85.1                                                                             
  No prediction made (drug profile prediction incomplete)                                                                  U                           S or U                                  150                                                                                 126 (84.0)                                                                       
  At least one F, no R                                                                                                     280                         240 (85.7)                                                                                                                                                                                                   
  At least one R and U, no F                                                                                               499                         6 (1.2)                                                                                                                                                                                                      
  At least one R and F, no U                                                                                               159                         3 (1.9)                                                                                                                                                                                                      
  At least one R, U, and F                                                                                                 18                          0 (0.0)                                                                                                                                                                                                      
                                                                                                                           Total                       1106                                    375 (33.9)                                                                                                                                                           

As the proportion of incompletely predicted profiles was substantial (22.0%), we assessed whether pan-susceptibility could be accurately predicted for some of these isolates anyway. Because isoniazid susceptibility predicts susceptibility to other first-line drugs,[@B15] we maximised confidence in isoniazid predictions by conditioning predictions on the absence of 'unknown' mutations in isoniazid- related genes. 'Unknown' mutations relevant to other drugs were permitted. Doing this, pan- susceptibility was correctly predicted for 4,481/4,582 (97.8%) isolates, including 545/1,651 (33.0%) previously incompletely predicted profiles ([Table 4](#T4){ref-type="table"}). Among the collections unenriched for resistance, 3439/3450 (99.7%) profiles were thereby correctly predicted pan-susceptible ([S7](#SD1){ref-type="supplementary-material"}).

To simulate how this approach would perform in settings with differing burdens of antimicrobial resistance, we assessed the decline in negative predictive value with increasing prevalence of resistance to individual drugs, and with prevalence of any resistance within drug profiles. We randomly sub-sampled 1,000 isolates to represent every 1% increment in antimicrobial-resistance prevalence between 10%-90%, repeating this 1,000 times for each drug and for complete drug profiles. Negative predictive value declined further for ethambutol and pyrazinamide than for complete drug profiles, but declined least for isoniazid and rifampicin. Below 47.0% prevalence of resistance to any drug, the simulated negative predictive value remained above 95% for 97.5% of drug profiles ([Figure 1](#F1){ref-type="fig"}).

![Simulated negative predictive values for individual drugs and complete drug profiles\
Negative predictive vales shown for individual drugs and complete drug profiles, according to simulated prevalence of resistance to each drug, or within each drug profile ('any resistance'). For each percentage prevalence between 10% and 90%, 1,000 isolates were randomly selected, 1,000 times. Lines indicate the median with shaded areas showing the 95% confidence intervals.](NEJMoa1800474_Walker_fig1){#F1}

Discrepancy analyses
--------------------

In Australia, eleven ethambutol susceptible isolates containing *embB* mutations were re- phenotyped. Three repeat assays failed, but seven of the remaining eight yielded, now consistent, resistant phenotypes. In Peru, 10 of 16 repeated assays remained phenotypically susceptible by MODS despite *fabG1* C-15T or G-17T mutations. In isolates from the Netherlands, six resistant phenotypes predicted susceptible were identified as clerical errors, and three susceptible phenotypes predicted resistant tested phenotypically resistant by alternative phenotypic assays ([S8](#SD1){ref-type="supplementary-material"}). Although additional re- phenotyping was not possible, we conducted a 'per mutation' analysis to further assess discrepancies.

Of the 322 resistant phenotypes predicted susceptible, 290 (90.1%) had no mutations affecting targeted genes, and 32 (9.9%) had one or more of 15 mutations per isolate, each previously characterised as consistent with antimicrobial susceptibility. Supporting this, across all isolates in which these 15 mutations occurred as the sole mutation, they correctly predicted isoniazid susceptibility in 286/293 (97.6%) isolates and ethambutol susceptibility in 95/119 (79.8%) isolates. The one mutation relevant to pyrazinamide was seen in two isolates, both of which were phenotypically resistant. None of these mutations were relevant to rifampicin ([S9](#SD1){ref-type="supplementary-material"}).

Among 822 susceptible phenotypes predicted resistant, 145 different resistance-conferring mutations were found. Of these, 142 (97.9%) featured as the only resistance-conferring mutation in at least one isolate in the dataset, allowing assessment of individual predictive performance. They correctly predicted resistance to isoniazid in 308/371 (83.0%) isolates, rifampicin in 548/627 (87.4%) isolates, ethambutol in 1280/1743 (73.4%) isolates, and pyrazinamide in 459/663 (69.2%) isolates (S9). 14 of 17 (82.3%) mutations leading to rifampicin resistance predictions in phenotypically susceptible isolates were in the genetic region targeted by Xpert MTB/RIF and MTBDR*plus*.

Laboratory sample mislabelling probably also contributed discrepant results. This was estimated for each collection from the proportion of isolates excluded because of *katG* S315T or *rpoB* S450L mutations and susceptible phenotypes, the collection's discrepancy rate, and the prevalence of antimicrobial resistance ([S10](#SD1){ref-type="supplementary-material"}). Overall, about 43% of isoniazid, and 12% of rifampicin discrepancies were thereby attributable to mislabelling.

Discussion
==========

This analysis of over 10,000 *M. tuberculosis* isolates collected from 16 countries across six continents, and representing all major lineages, demonstrates that whole-genome sequencing can now characterise susceptible first-line anti-tuberculosis drug profiles sufficiently accurately for clinical use. The importance of this is twofold: First, it demonstrates that the genomic approach can be used to tailor individual treatment regimens. Extended to all drugs, individualised therapies promise to improve cure rates over those achieved by semi-empiric regimens directed by more limited diagnostic tests.1 Second, it is now possible to reduce the phenotypic workload where routine whole-genome sequencing is performed.

The WHO's target product profiles for new molecular assays for *M. tuberculosis* require over 90% and 95% sensitivity and specificity, respectively.[@B7] Overall, both these targets were met for all drugs with the exception of specificity for ethambutol (93.6%). This is no surprise as phenotyping is an imperfect gold standard, in particular for isolates with *embB* mutations.[@B6] For the collections unenriched for resistance, all drugs did however meet these targets, as did the predictions of pan- susceptibility in all collections. Only categorical agreement was assessed for complete drug profile predictions because of the number of permutations. These met the external quality assurance criteria (\>80% concordance) for the European TB reference laboratory network.[@B17]

There are three reasons why pan-susceptibility predictions were particularly accurate. First, the knowledgebase included both resistance-associated genomic mutations, and mutations compatible with phenotypic susceptibility. Second, anti-tuberculosis drug susceptibility phenotypes are not independent of one another, allowing the use of isoniazid susceptibility to predict susceptibility to other drugs. Third, no predictions were attempted for isolates containing genomic variation of unknown association in genes affecting isoniazid. This maximised confidence in isoniazid predictions that were made. Consequently, the prediction of drug profiles performed better than the per-drug analysis for ethambutol and pyrazinamide, and although there was a slight corresponding decline in performance for isoniazid and rifampicin, simulations showed that the prevalence of resistance would have to exceed that seen in most of the worst affected countries in the world before these predictions no longer satisfied the WHO targets.[@B1]

Our findings showed substantial improvements over the *in-silico* predictions for the sensitivity of WHO-recommended PCR-based assays because whole-genome sequencing is able to identify many more mutations. These additional mutations were however simultaneously responsible for the losses in specificity, largely because of the number of mutations for which a minority of isolates did not manifest a resistant phenotype. A typical example of such is the *rpoB* I491F mutation which frequently gives a susceptible rifampicin result in liquid culture but has been linked to treatment failure.[@B4]

The broader discrepancy analysis highlighted the same phenomenon. Whilst the predictive performance of individual mutations, whether probed by WHO-recommended assays or not, was good, each mutation has an error rate, occasionally leading to an unexpected phenotype in a minority of isolates. This is most likely where a mutation elevates the minimum drug concentration required to inhibit bacterial growth to close to the concentration above which an isolate is considered resistant. Canonical ethambutol mutations are a classic example,[@B20] but there are many others including the mutations missed by the MODS assay in Peru.[@B16] Such phenomena are thus likely to explain the majority of isolates that were predicted resistant, yet were phenotypically susceptible. They are also the most likely reason why predicting pan-susceptible drug profiles was more accurate than predicting profiles apparently resistant to one or more drugs.

One study limitation is that the scale and cost of repeat sequencing and phenotyping of isolates meant that we could not definitively resolve most discrepancies. This was most concerning for phenotypically resistant isolates predicted susceptible. For these, possible explanations include phenotypic error, resistant minority bacterial populations undetected by sequencing, mechanisms of resistance linked to genes we did not interrogate, or laboratory labelling error.

More work remains to be done before predictions can be extended to second and third-line drugs, and to newer compounds. However, following external review, Public Health England has already decided to stop phenotyping isolates predicted pan-susceptible to first-line drugs (personal communication, Derrick Crook, Director, National Infection Service). Similar moves are expected in the Netherlands (Dick van Soolingen, Rijksinstituut voor Volksgezondheid en Milieu) and New York (Kimberlee Musser, Wadsworth Center, New York State Department of Health). For low and middle- income countries without easy access to phenotyping, there is now the prospect that emerging mobile sequencing platforms could be used to implement sequence-directed therapies, a potential solution to the call for universal susceptibility testing. Portable platform sequencing directly from spiked-samples has been achieved, although real-world systematic evaluation is still required.[@B23]

Should whole-genome sequencing perform as well for second and third-line drugs as for first- line, a clinical trial could be needed to assess the performance of individualised over standardized treatment regimens in countries with a high drug-resistant disease burden.[@B24] Individualised therapies would be expected to reduce the amplification of resistance (to other drugs) in individual patients, side- effects, likelihood of onward transmission, and to exert a weaker selection pressure on strains at a population level, which is key where empiric regimens have been targeted on the basis of very narrow data on antimicrobial susceptibility.[@B4] Welcome public health benefits could result from monitoring transmission using the very same sequences.[@B2]

The current investment in whole-genome sequencing in high-income countries is likely to help accelerate implementation in lower-income, higher-burden countries where the potential benefit is greatest.[@B25] These data demonstrate how our understanding of the molecular determinants of resistance to first-line anti-tuberculosis drugs is now sufficiently good to start using DNA sequencing to guide therapy. Similar performance must now be replicated for the remaining drugs.
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